Enlivex Therapeutics Ltd. (NASDAQ:ENLV) announced promising three-month outcomes from its Phase IIa study evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis.
The company’s stock surged 18% following the announcement.
The randomized, double-blind, placebo-controlled, multi-center trial demonstrated a 24% reduction in knee pain and a 26% improvement in function across the modified intention-to-treat population treated with Allocetra compared to placebo.
Notably, in a subgroup of patients with age-related primary osteoarthritis, the therapy delivered particularly strong results, showing a 72% drop in pain and a 95% improvement in knee function, which the company emphasized were statistically significant.
No serious safety concerns were observed during the trial. Reported side effects were generally mild to moderate and temporary. Enlivex, headquartered in Nes-Ziona, Israel, specializes in macrophage reprogramming immunotherapies.
“We believe these results provide clear indication that Allocetra has the potential to become a novel, safe and effective treatment for knee osteoarthritis,” said CEO Oren Hershkovitz.
The company also held a webinar to provide further details of the findings. The ENX-CL-05-001 trial is structured as a two-stage Phase I/II program assessing Allocetra in patients with moderate-to-severe knee osteoarthritis.
Enlivex Therapeutics stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.